Clinical Trials Logo

Clinical Trial Details — Status: Unknown status

Administrative data

NCT number NCT01501617
Other study ID # 11-HIS006-PH
Secondary ID
Status Unknown status
Phase Phase 1/Phase 2
First received December 22, 2011
Last updated January 13, 2012
Start date December 2011
Est. completion date December 2012

Study information

Verified date January 2012
Source Histogen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy in relation to dosing in the administration of Hair Stimulating Complex (HSC) in healthy men. HSC will be injected intradermally in the scalps of men with male pattern baldness (i.e. androgenetic alopecia).


Description:

HSC consists of proteins secreted by human dermal cells under proprietary culture conditions that include reduced oxygen and bioreactors. Under these conditions, the cells secrete soluble proteins that include both growth factors and soluble precursors to the deposited extracellular matrix. Several of these proteins are known to be important in the control of the hair cycle and will stimulate resting hair follicles to resume hair formation.


Recruitment information / eligibility

Status Unknown status
Enrollment 56
Est. completion date December 2012
Est. primary completion date June 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria:

1. Male, ages 21-65 years.

2. A healthy scalp with no cutaneous disorder.

3. Subject should be in good general health.

4. Male subjects must be classified 3 Vertex, 4, 4A (if large enough), 5, 5A, or 6 under the Norwood-Hamilton Classification for Male Pattern Hair Loss (See Appendix 1).

5. Subject must be Fitzpatrick Type I, II, III and IV skin pigmentation (See Appendix 2). Type IV is acceptable however Type I-III is preferable.

6. Willing and able to comply with scheduled visits (Total: 7 visits in 48 weeks)

7. Willing to maintain the same hair style during the study period.

8. Willing to have a total of four microscopic dot tattoos. Two tattoos per treatment site (one in the center and one on the edge) of the two target regions of the scalp at miniaturization zone.

9. Willing to have 2 cm2 hairs clipped at treatment areas.

10. Willing to forgo the use of scalp products, including dye, throughout the study except for study related dye.

11. Willing to use a mild, a non-ionic shampoo throughout the course of the study.

Exclusion Criteria:

1. History of keloid formation or hyperpigmentation.

2. A history of any acute or chronic illness that in the opinion of the investigators might confound the results of the study including some drugs or medications.

3. Active skin diseases (e.g. eczema, atopic dermatitis, psoriasis, skin cancer, sun damaged skin with actinic keratosis on scalp, etc.).

4. Routine high dosage use of anti-inflammatory medications (aspirin, ibuprofen, corticosteroids), immunosuppressive drugs or antihistamine medications (steroid nose drops and/or eye drops are permitted). Two 81 mg or one 325 mg aspirin per day is also acceptable.

5. Use of topical drugs or other cosmetics on the scalp.

6. Immunological disorders such as HIV positive, alopecia areata, and systemic lupus erythematosus.

7. Participation in any clinical study within the last four weeks.

8. Moderate or severe seborrheic dermatitis of scalp.

9. Damaged skin in or around test sites including sunburn, uneven skin tones, tattoos, scars or other disfiguration of the test site.

10. Use of OTC (over-the-counter) or prescriptive topical or hair treatments, as well as hair transplantation surgery during the last 6 months. This includes Minoxidil 2% or 5% and/or Finasteride 1mg or any 5alpha-reductase inhibitors.

11. Currently using hair system or wig.

12. Presence of hair transplants or scalp surgery.

13. History of allergy or intolerance to lidocaine and/or epinephrine.

14. Use of hair dye (not study related) during the study duration.

15. Any condition for which the Investigator determines that the subject could be placed under undue risk.

16. Reported history of allergy or intolerance to bovine proteins.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Hair Stimulating Complex (HSC)
Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.
Device:
Dulbecco's Modified Eagle Medium, DMEM
Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.

Locations

Country Name City State
Philippines The Medical City Pasig City Manila

Sponsors (2)

Lead Sponsor Collaborator
Histogen Gleneagles CRC Pte Ltd.

Country where clinical trial is conducted

Philippines, 

Outcome

Type Measure Description Time frame Safety issue
Primary Systemic safety measures will be assessed by measuring vital signs, adverse experiences, laboratory tests (hematology, clinical chemistry and urinalysis)and immunological response (anti-drug antibodies) Clinically significant change from screening visit to Week 12
Primary Non-vellus hair counts Change from Baseline to week 12 in treatment areas
Secondary Hair Thickness Density Change from Baseline to week 48 in treatment areas
Secondary Local safety measures will be assessed by clinical exam of treatment areas and monitoring adverse events Clinically significant change from Screening visit to Week 48
See also
  Status Clinical Trial Phase
Completed NCT02591355 - Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment N/A
Withdrawn NCT03852992 - Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Phase 2
Recruiting NCT06239207 - Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia Phase 2
Completed NCT04945226 - A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001 Phase 1/Phase 2
Completed NCT01548066 - The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss Phase 2
Completed NCT01437163 - Treatment of Androgenetic Alopecia in Males and Females N/A
Completed NCT01226459 - Clinical Trial in Females for Female Pattern Hair Loss Phase 3
Recruiting NCT06118866 - A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia Phase 2
Completed NCT06149221 - Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss N/A
Withdrawn NCT04882969 - Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia N/A
Completed NCT01231607 - Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Phase 3
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Completed NCT02729415 - Point-of-Care Adipose-derived Cells for Hair Growth N/A
Completed NCT02279823 - A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia Phase 2
Not yet recruiting NCT01227031 - Pharmacogenomic Study of Androgenetic Alopecia N/A
Completed NCT00981461 - Treatment of Androgenetic Alopecia in Females, 9 Beam N/A
Completed NCT01451021 - A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Phase 2
Completed NCT00151515 - A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Phase 3
Completed NCT03694067 - Androgenetic Alopecia and the JAK-STAT Pathway
Completed NCT03689452 - The Effect of Platelet Rich Plasma on Non-scarring Alopecia N/A